Sękowska, A. In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex. Antibiotics2024, 13, 126.
Sękowska, A. In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex. Antibiotics 2024, 13, 126.
Sękowska, A. In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex. Antibiotics2024, 13, 126.
Sękowska, A. In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex. Antibiotics 2024, 13, 126.
Abstract
Klebsiella pneumoniae complex is one of the most commonly isolated bacteria within human infections. These microorganisms are opportunistic pathogens that pose a serious threat to public health due to possibility of transmission in the human population. Resistance to carbapenems is one of the most important antimicrobials resistance mechanisms amongst them. In this situation therapeutic options are limited. Therefore, the aim of this study was to evaluate fosfomycin, colistin, ceftazidime-avibactam and meropenem-vaborbactam in vitro activity against multidrug-resistant K. pneumoniae complex strains. The study involved 160 strains of Gram-negative rods: K. pneumoniae – 138 and K. variicola - 22. Minimal inhibitory concentration of fosfomycin was estimated by agar dilution method and for colistin by microdilution method. The susceptibility to ceftazidime-avibactam and meropenem-vaborbactam was determined by gradient strip method. All of the analysed K. pneumoniae complex isolates produced extended-spectrum beta-lactamases and 60.0% carbapenemases. The most of the analysed strains were susceptible to fosfomycin and colistin (62.5%). Among pandrug-resistant K. pneumoniae complex isolates the most were susceptible to colistin (43.9%). Fosfomycin has good activity against ESBL- and VIM-positive isolates from this complex. In turn, colistin has satisfactory in vitro activity against KPC- and VIM-positive isolates from K. pneumoniae complex. Ceftazidime-avibactam has good activity against K. pneumoniae complex strains producing ESBL, KPC and OXA enzymes. In turn, meropenem-vaborbactam has satisfactory in vitro activity against ESBL- and KPC-positive isolates from this complex.
Keywords
ceftazidime-avibactam, colistin, fosfomycin, K. pneumoniae, K. variicola, meropenem-vaborbactam
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
